|
Suppliers for CAS
862507-23-1
|
Properties | | CAS |
862507-23-1 | | Formula |
C24H29FN6.2CH4O3S |
|
6 Registered suppliers
Capot Chemical Co., Ltd.
P.R.China
More details are to be found here
Leap Chem Co., Ltd
P.R.China
Molecular Formula: C26H37FN6O6S2
Molecular Weight: 612.7369832
Aea.ltd
P.R.China
Molecular Formula: C26H37FN6O6S2
Molecular Weight: 612.7369832
BOC Sciences
USA
Description : LY2228820 dimesylate is the salt form of LY2228820, a tri-substituted imidazole derivative and p38α and β MAPK inhibitor. LY2228820 inhibits tumor growth in various cancer models. - Molecular Weight :612.74
- Purity :> 98%
Molecular Formula : C26H37FN6O6S2 Canonical SMILES : CC(C)(C)CN1C2=C(C=CC(=N2)C3=C(N=C(N3)C(C)(C)C)C4=CC=C(C=C4)F)N=C1N.CS(=O)(=O)O.CS(=O)(=O)O
InChI :
InChI=1S/C24H29FN6.2CH4O3S/c1-23(2,3)13-31-20-17(28-22(31)26)12-11-16(27-20)19-18(14-7-9-15(25)10-8-14)29-21(30-19)24(4,5)6;2*1-5(2,3)4/h7-12H,13H2,1-6H3,(H2,26,28)(H,29,30);2*1H3,(H,2,3,4)
InChIKey :
NARMJPIBAXVUIE-UHFFFAOYSA-N
Synonyms :
Ralimetinib Mesylate; Ralimetinib dimesylate; 5-[2-tert-butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)imidazo[4,5-b]pyridin-2-amine mesylate
More details are to be found here
Chemos GmbH & Co. KG
Germany
Description : LY2228820 dimesylate is the salt form of LY2228820, a tri-substituted imidazole derivative and p38α and β MAPK inhibitor. LY2228820 inhibits tumor growth in various cancer models. - Molecular Weight :612.74
- Purity :> 98%
Molecular Formula : C26H37FN6O6S2 Canonical SMILES : CC(C)(C)CN1C2=C(C=CC(=N2)C3=C(N=C(N3)C(C)(C)C)C4=CC=C(C=C4)F)N=C1N.CS(=O)(=O)O.CS(=O)(=O)O
InChI :
InChI=1S/C24H29FN6.2CH4O3S/c1-23(2,3)13-31-20-17(28-22(31)26)12-11-16(27-20)19-18(14-7-9-15(25)10-8-14)29-21(30-19)24(4,5)6;2*1-5(2,3)4/h7-12H,13H2,1-6H3,(H2,26,28)(H,29,30);2*1H3,(H,2,3,4)
InChIKey :
NARMJPIBAXVUIE-UHFFFAOYSA-N
Synonyms :
Ralimetinib Mesylate; Ralimetinib dimesylate; 5-[2-tert-butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)imidazo[4,5-b]pyridin-2-amine mesylate
More details are to be found here
Santa Cruz Biotechnology, Inc.
USA
Description : LY2228820 dimesylate is the salt form of LY2228820, a tri-substituted imidazole derivative and p38α and β MAPK inhibitor. LY2228820 inhibits tumor growth in various cancer models. - Molecular Weight :612.74
- Purity :> 98%
Molecular Formula : C26H37FN6O6S2 Canonical SMILES : CC(C)(C)CN1C2=C(C=CC(=N2)C3=C(N=C(N3)C(C)(C)C)C4=CC=C(C=C4)F)N=C1N.CS(=O)(=O)O.CS(=O)(=O)O
InChI :
InChI=1S/C24H29FN6.2CH4O3S/c1-23(2,3)13-31-20-17(28-22(31)26)12-11-16(27-20)19-18(14-7-9-15(25)10-8-14)29-21(30-19)24(4,5)6;2*1-5(2,3)4/h7-12H,13H2,1-6H3,(H2,26,28)(H,29,30);2*1H3,(H,2,3,4)
InChIKey :
NARMJPIBAXVUIE-UHFFFAOYSA-N
Synonyms :
Ralimetinib Mesylate; Ralimetinib dimesylate; 5-[2-tert-butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)imidazo[4,5-b]pyridin-2-amine mesylate
More details are to be found here
|
details
details